US2015017180A1PendingUtilityA1

Treatment of chronic inflammatory conditions

Assignee: CSL LTDPriority: Feb 18, 2009Filed: May 12, 2014Published: Jan 15, 2015

Est. expiryFeb 18, 2029(~2.6 yrs left)· nominal 20-yr term from priority

Inventors:Gino Luigi Vairo John Allan Hamilton Andrew David Cook

C07K 2317/73C07K 2317/76C07K 16/244A61K 38/202A61K 39/3955A61K 51/1033A61K 2039/505C07K 16/2866A61K 51/1021C07K 2317/72A61K 38/1793C07K 2317/732C07K 2317/21A61P 19/02C07K 2317/52C07K 2317/734C07K 2317/24C07K 2317/41

PatentIndex Score

Cited by

References

Claims

Abstract

A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient.

Claims

exact text as granted — not AI-modified

1 - 38 . (canceled) 
     
     
         39 . A method for the treatment of a chronic inflammatory condition in a patient in need thereof, which comprises administration to the patient of an antibody which selectively binds to IL-3R alpha and wherein the antibody has a modified Fc region to provide enhanced effector function. 
     
     
         40 . The method according to  claim 39  wherein the chronic inflammatory condition is urticarial 
     
     
         41 . The method according to  claim 39  wherein the enhanced effector function is selected from the group consisting of enhanced binding to Fc receptors, enhanced ADCC activity, enhanced ADCP activity and enhanced CDC activity. 
     
     
         42 . The method according to  claim 39  wherein the antibody has enhanced ADCC activity. 
     
     
         44 . The method according to  claim 42  wherein the antibody is afucosylated. 
     
     
         45 . The method according to  claim 39  wherein the urticaria is chronic urticaria.

Join the waitlist — get patent alerts

Track US2015017180A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.